ArticleOncotarget2017
Suppression of immune regulatory cells with combined therapy of celecoxib and sunitinib in renal cell carcinoma.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 30 citations in OpenAlex.
- CAIX-targeted radiotracer for diagnosis and monitoring VEGFR-TKI response in clear cell renal cell carcinoma.European journal of nuclear medicine and molecular imaging · 2026Article
- Exploring the celecoxib-cervical cancer relationship usingFrontiers in medicine · 2026Article
- Treatment of cancer-associated fibroblast-like cells with celecoxib enhances the anti-cancer T helper 1/Treg responses in breast cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- COX 2-inhibitors; a thorough and updated survey into combinational therapies in cancers.Medical oncology (Northwood, London, England) · 2024Review
- Article
- The recent progress of myeloid-derived suppressor cell and its targeted therapies in cancers.MedComm · 2023Review
- Role of myeloid-derived suppressor cells in the formation of pre-metastatic niche.Frontiers in oncology · 2022Review
- Review
- Review
- Photochemically-Induced Release of Lysosomal Sequestered Sunitinib: Obstacles for Therapeutic Efficacy.Cancers · 2020Article
- Regulation of heterotopic ossification by monocytes in a mouse model of aberrant wound healing.Nature communications · 2020Article
- Fabrications of boron-containing apatite ceramics via ultrasonic spray-pyrolysis route and their responses to immunocytes.Journal of materials science. Materials in medicine · 2020Article
- Selenium and selenoproteins in prostanoid metabolism and immunity.Critical reviews in biochemistry and molecular biology · 2019Review
- Tumour-associated neutrophils in patients with cancer.Nature reviews. Clinical oncology · 2019Review
- Celecoxib Inhibits Hepatocellular Carcinoma Cell Growth and Migration by Targeting PNO1.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Significance of cyclooxygenase-2, prostaglandin E2 and CD133 levels in sunitinib-resistant renal cell carcinoma.Oncology letters · 2019Article
- Targeting Myeloid Cells in Combination Treatments for Glioma and Other Tumors.Frontiers in immunology · 2019Review
- HPV16 E7 increases COX-2 expression and promotes the proliferation of breast cancer.Oncology letters · 2018Article
- Inhibition of COX2 enhances the chemosensitivity of dichloroacetate in cervical cancer cells.Oncotarget · 2017Article
- Targeted therapies for renal cell carcinoma.Nature reviews. Nephrology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo observe the the potential benefit of sunitinib in combination with cyclooxygenase-2(COX-2) inhibitor in renal cell carcinoma therapy.
methods769-p cell lines were treated with sunitinib, celecoxib, or in combination at different concentrations respectively. We investigated the expression of granulocyte-macrophage colony stimulating factor (GM-CSF) in 769-p and cell proliferation in vitro. BALB/c mice implanted with Renca cells were divided into 4 groups and administered orally by gavage with sunitinib, COX-2 inhibitor (celecoxib) monotherapy or combination, and PBS respectively. Tumor growth and animal survival were observed. The myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) in peripheral blood and spleen were determined by flow cytometry. The MDSCs protein was extracted for STAT3 analysis by western blot.
results769-p cell lines were suppressed in a dose and time-dependent manner. The expression of GM-CSF was substantially inhibited by celecoxib and sunitinib. Combination of sunitinib and celecoxib in vivo could effectively reduce the MDSCs than those in control group. Meanwhile, the CD4+ lymphocytes were strongly increased and the expression of signal transducer and activator of transcription 3 (STAT3) in MDSCs were significantly reduced.
conclusionCombination therapy with sunitinib and celecoxib intensified the curative effects to renal cell carcinoma by suppressing immune regulatory cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.